Summit completes enrollment in Phase II DMD trial, receives $22M milestone from Sarepta

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) completed enrollment in the Phase II PhaseOut DMD trial of ezutromid (SMT C1100) to treat Duchenne muscular dystrophy (DMD), triggering a $22 million milestone payment from partner Sarepta Therapeutics Inc. (NASDAQ:SRPT).

The open-label, U.S. and U.K. Phase II PhaseOut DMD trial enrolled 40 ambulatory boys ages 5-10 with DMD to receive twice-daily 2.5 g oral ezutromid for 48 weeks. ...